]>Circulating Tissue Inhibitor of Matrix Metalloproteinase-4 (TIMP-4) in Systemic Sclerosis Patients with Elevated Pulmonary Arterial Pressure : Table 4
Table 4: Echocardiography-derived measurements of myocardial performance and BNP blood levels (mean ± SD) in SSc patients with normal or elevated PASP.
RV Tei-indexLV Tei-indexLV EF (%)BNP (pg/mL)
PASP ≤40 mm Hg (all patients, 𝑛 = 69) 0 . 3 7 ± 0 . 0 2 0 . 3 8 ± 0 . 0 1 61 ± 933 ± 23
PASP >40 mm Hg (all patients, 𝑛 = 37) 0 . 4 1 ± 0 . 0 3 ( 𝑃 < . 0 0 1 ) ∗ 0 . 4 1 ± 0 . 0 2 ( 𝑃 < . 0 0 1 ) ∗ 60 ± 5163 ± 159 ( 𝑃 < . 0 0 0 1 ) ∗
PASP >40 mm Hg (diffuse SSc, 𝑛 = 21) 0 . 4 1 ± 0 . 0 3 0 . 4 1 ± 0 . 0 2 60 ± 5167 ± 187
PASP >40 mm Hg (limited SSc, 𝑛 = 16) 0 . 4 2 ± 0 . 0 3 0 . 4 0 ± 0 . 0 2 61 ± 4164 ± 120
SSc: systemic sclerosis;  PASP: pulmonary artery systolic pressure;  BNP: B-type natriuretic peptide;  RV: right ventricular;  LV: left ventricular;  EF: ejection fraction.*Comparing to patients with PASP ≤40.